The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
Each year, ADI hosts its Alzheimer University for emerging associations, aiming to equip new associations with the skills and knowledge needed to run a successful Alzheimer or dementia association.
Lecanemab represents the first antibody treatment for Alzheimer’s disease to have received traditional approval from the Food and Drug Administration in the US.
Her Royal Highness Princess Muna Al Hussein is the fourth global Ambassador of ADI, joining Queen Silvia of Sweden, Queen Sofia of Spain and the Luis Guillermo Solís Rivera, former President of Costa Rica.
The month of March has marked significant progress in the development and implementation of National Dementia Plans (NDPs), with the #WhatsYourPlan campaign leading to the launch of plans in Uruguay and Armenia, bringing the total number of WHO Member States with NDPs to 41.
Lecanemab is the second Alzheimer’s disease pharmaceutical treatment to come to market since 2003, following the conditional approval of Aduhlem (aducanumab) in June 2022.
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
A joint letter was submitted in anticipation of the 3rd session of the World Health Organization's Intergovernmental Negotiating Body on 5-7 December.